Treatment of 212 patients with limited-disease small cell lung cancer
- VernacularTitle:212例局限期小细胞肺癌放射及综合治疗效果
- Author:
Guimei LIU
;
Kunliang SUN
;
Guangrong XIA
- Publication Type:Journal Article
- Keywords:
Small cell lung carcinoma;
Radiotherapy;
Chemotherapy;
Combined modality treatment;
Prognosis
- From:
Chinese Journal of Radiological Medicine and Protection
2008;28(4):381-385
- CountryChina
- Language:Chinese
-
Abstract:
Objective To review the treatment effect of limited disease small cell lung cancer (LD-SCLC) and to evaluate the prognosis factors for SCLC. Methods From Aug. 2002 to Feb. 2006, 212 patients of SCLC confirmed with pathology and cytology were. Treated by combined modality. All patients were treated with chemotherapy 2-6 cycles, 59 patients of which were treated with only chemotherapy, 108 patients of which were treated with chemotherapy plus radiotherapy, 45 patients of which were treated with surgery plus chemotherapy with or without radiotherapy. The patients of radiotherapy were exposed to 6 or 10 MV X-ray with a total dose of 40-66 Gy in 4-7 weeks. Results The overall median survival time was 15 months. The 1-,2- and 3-year overall survival rate were 58.0%, 33.2% and 22.1%, respectively. Univariate analysis indicated that weight loss, age, LDH, ECOG performance status, operation, response to radio-chemotherapy, cycles for chemotherapy, radiotherapy irflueoced survival significantly in LD-SCLC. Multivariate analysis suggested that ECOG performance status, response to therapy, cycles for chemotherapy were the independent prognostic factors for LD-SCLC. Conclusions For LD-SCLC patients, ECOG performance ≤ 1, good response to radio-chemotherapy, and ≥ 4 cycles chemotherapy show encouraging survival rate, Distance metastasis is still the mainstay of treatment failure.
